Repligen to buy BioLife Solutions in $1.5 billion deal
Repligen to buy BioLife Solutions in $1.5 billion deal July 22 (Reuters) - Repligen Corp RGEN.O said on Wednesday it would buy BioLife Solutions BLFS.O , a cell-and-gene-therapy tools maker, in a deal valued at about $1.5 billion to expand its presence in the fast-growing cell therapy market.
(Reporting by Sahil Pandey in Bengaluru; Editing by Tasim Zahid)
Recent news on BioLife Solutions
See all newsFreshworks gains ahead of S&P SmallCap 600 inclusion
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: S&P Dow Jones Indices Freshworks Set To Join S&P Smallcap 600
BioLife Solutions, Inc. reports results for the quarter ended June 30 - Earnings Summary